OptimizeRx Co. (NASDAQ:OPRX) Given Average Rating of “Moderate Buy” by Analysts

OptimizeRx Co. (NASDAQ:OPRX) has received an average recommendation of “Moderate Buy” from the nine research firms that are presently covering the company, MarketBeat.com reports. Three research analysts have rated the stock with a hold recommendation, five have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $9.06.

A number of research analysts have commented on OPRX shares. B. Riley upgraded shares of OptimizeRx to a “strong-buy” rating in a research note on Wednesday, March 12th. JMP Securities restated a “market outperform” rating and set a $8.00 target price on shares of OptimizeRx in a research report on Thursday, February 6th. Lake Street Capital reaffirmed a “buy” rating and issued a $11.00 price target on shares of OptimizeRx in a research note on Tuesday, December 24th. Finally, Royal Bank of Canada reiterated a “sector perform” rating and set a $6.00 price objective (down from $7.00) on shares of OptimizeRx in a research note on Wednesday, January 8th.

OptimizeRx Trading Up 3.3 %

Shares of OPRX stock opened at $8.45 on Friday. The company has a debt-to-equity ratio of 0.29, a quick ratio of 3.23 and a current ratio of 3.23. The firm has a fifty day moving average of $7.14 and a 200-day moving average of $6.05. OptimizeRx has a 52-week low of $3.78 and a 52-week high of $14.13. The stock has a market cap of $156.24 million, a price-to-earnings ratio of -6.35 and a beta of 1.18.

Insider Activity

In related news, Director James Paul Lang acquired 321,408 shares of the firm’s stock in a transaction on Friday, March 14th. The shares were purchased at an average price of $7.60 per share, with a total value of $2,442,700.80. Following the acquisition, the director now directly owns 389,452 shares in the company, valued at $2,959,835.20. The trade was a 472.35 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link. 6.10% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On OptimizeRx

A number of large investors have recently modified their holdings of OPRX. Barclays PLC increased its holdings in shares of OptimizeRx by 358.5% in the third quarter. Barclays PLC now owns 26,934 shares of the company’s stock valued at $208,000 after purchasing an additional 21,060 shares in the last quarter. BNP Paribas Financial Markets increased its stake in shares of OptimizeRx by 189.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 3,690 shares of the company’s stock valued at $28,000 after buying an additional 2,414 shares during the period. Whetstone Capital Advisors LLC bought a new stake in shares of OptimizeRx during the fourth quarter worth $6,563,000. Kennedy Capital Management LLC lifted its stake in shares of OptimizeRx by 57.8% during the fourth quarter. Kennedy Capital Management LLC now owns 594,000 shares of the company’s stock valued at $2,887,000 after acquiring an additional 217,676 shares during the period. Finally, Royce & Associates LP bought a new position in OptimizeRx in the fourth quarter valued at about $5,198,000. 76.47% of the stock is currently owned by institutional investors and hedge funds.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.